Screener
King Pharmaceuticals KG Fixed Maturities, Fair Value
Fixed Maturities, Fair Value at other companies
Other financials
Where this comes from
Reported directly by King Pharmaceuticals in its filing.
Tagged under the XBRL concept kg:FixedMaturitiesFairValue.
The source filing: King Pharmaceuticals’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 8:49 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-054606
| June 30, 2026 | Amortized cost | Fair value | % of Total fair value |
|---|---|---|---|
| U.S. treasury bills | $35,027 | $35,026 | 24.2% |
| U.S. agency bonds – mortgage-backed | 20,002 | 20,346 | 14.1% |
| AAA | 37,002 | 36,955 | 25.5% |
| AA+, AA, AA- | 17,899 | 17,873 | 12.4% |
| A+, A, A- | 34,103 | 33,923 | 23.5% |
| BBB+, BBB, BBB- | 500 | 501 | 0.3% |
| Total fixed maturities (1) | $144,533 | $144,624 | 100.0% |
Item 1. Financial Statements
FAQ
- What is King Pharmaceuticals's fixed maturities, fair value?
- King Pharmaceuticals (KG) reported fixed maturities, fair value of $144.62M in Q2 2026.
- What does fixed maturities, fair value mean?
- Fixed Maturities, Fair Value as reported by Kestrel Group Ltd.
Ask your AI about King Pharmaceuticals's fixed maturities, fair value.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude